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Abstract
Background—A rapid increase in multidrug-resistant Gram-negative infections has led to a 
reemergence of colistin use globally. Although it is well described among adults, colistin use and 
its associated toxicities in children are poorly understood. We report findings from the largest case 
series of pediatric colistin use to date.
Methods—We queried pediatric infectious diseases specialists from the Emerging Infections 
Network to identify members who had prescribed intravenous colistin within the past 7 years. We 
Copyright © 2012 by Lippincott Williams & Wilkins
Address for correspondence: Pranita D. Tamma, MD, Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins 
Medical Institutions, 200 North Wolfe Street, Suite 3155, Baltimore, MD 21287. ptamma1@jhmi.edu. 
The authors have no other funding or conflicts of interest to disclose.
HHS Public Access
Author manuscript
Pediatr Infect Dis J. Author manuscript; available in PMC 2015 May 11.
Published in final edited form as:













collected relevant demographic and clinical data. Bivariate analyses and multivariable logistic 
regression were performed.
Results—Two hundred twenty-nine pediatric infectious diseases specialists completed the 
survey (84% response); 22% had prescribed colistin to children. Among respondents, 92 cases of 
colistin use from 25 institutions were submitted. The most commonly targeted organisms were 
multidrug-resistant Pseudomonas (67.4%), multidrug-resistant Acinetobacter baumanii (11.9%), 
carbapenemase-producing Enterobacteriaceae (13.0%) and extended-spectrum β-lactamase 
producing Enterobacteriaceae (5.4%). Development of resistance to colistin was observed in 
20.5% of patients. Additional antimicrobial therapy was administered to 84% of patients, and 22% 
of children experienced nephrotoxicity (not associated with dosage or interval of colistin 
prescribed). Renal function returned to baseline in all patients. Children aged ≥13 years had 
approximately 7 times the odds of developing nephrotoxicity than younger children, even after 
controlling for receipt of additional nephrotoxic agents (odds ratio 7.16; 95% confidence interval: 
1.51–14.06; P = 0.013). Four children exhibited reversible neurotoxicity.
Conclusions—Most pediatric infectious diseases specialists have no experience prescribing 
colistin. Colistin use in children has been associated primarily with nephrotoxicity and, to a lesser 
extent, neurotoxicity, both of which are reversible. Emergence of resistance to colistin is 
concerning.
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The emergence of multidrug-resistant (MDR) Gram-negative organisms coupled with a lack 
of antimicrobials with activity against these bacteria has led to a renewed interest in the 
antibiotic colistin.1–6 The use of colistin was abandoned in the 1980s in favor of newer 
antibiotics that were perceived to have improved side-effect profiles; however, the ever-
growing problem of bacterial resistance has led to a reemergence of colistin use.7 Most 
Gram-negative pathogens remain susceptible to colistin, including MDR Acinetobacter 
baumannii, Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae.8
The efficacy and safety of colistin has been extensively studied in adults; nephrotoxicity and 
neurotoxicity have been reported to range between 3.5–58% and 0–7%, respectively.9–16 
Little is known about colistin use and its associated toxicities in children in the United 
States. Furthermore, optimal administration strategies (eg, dosing, interval) remain unclear. 
The objectives of this study were to describe current practices of prescribing colistin to 




This is a retrospective case series of colistin use among pediatric patients. To identify cases, 
we queried pediatric infectious diseases physician members of the Emerging Infections 
Network in January 2012 to identify members who have cared for children aged ≤18 years 
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who received intravenous colistin within the past 7 years. The Emerging Infections Network 
consists of 258 pediatric infectious diseases physicians in the United States, practicing in 44 
states (at the time of survey distribution). Members who indicated that they had prescribed 
colistin were requested to complete an electronic data collection form with patient-specific 
data. No patient identifiers were provided. The study was approved by the Johns Hopkins 
Hospital Institutional Review Board.
Data Collection
Patients were excluded if they received ≤72 hours of parenteral colistin. Data regarding 
demographic characteristics of the children receiving colistin, preexisting medical 
conditions, type of infections, isolated pathogens and travel to or from another country 
within 30 days before hospital admission were obtained. Additionally, characteristics of 
colistin treatment (dose, interval and duration), concomitant antibiotic treatment, use of 
additional potentially nephrotoxic agents, the emergence of colistin resistance, observed 
adverse events and clinical outcomes were recorded.
Definitions
Nephrotoxicity was defined as a creatinine clearance ≤60 mL/min if creatinine clearance 
was normal at baseline or a decrease in the category of clearance (mild 50–60 mL/min; 
moderate 10–50 mL/min; severe <10 mL/min). Use of additional nephrotoxic agents that 
were queried included amphotericin, aminoglycosides, cyclosporine, acyclovir, vancomycin, 
cidofovir, cyclophosphamide, methotrexate, cisplatin, nonsteroidal anti-inflammatory 
medications and intravenous contrast. The emergence of resistance to colistin was defined as 
a >2-fold increase in the minimum inhibitory concentration of colistin. Clinical cure was 
defined as resolution of signs and symptoms of infection at the discretion of the treating 
physician.
Statistical Analysis
Descriptive analyses included median and interquartile range for continuous data and 
proportions for categorical data. Bivariate analyses were performed using the Fisher exact 
test for categorical variables. The outcome of nephrotoxicity was assessed using regression 
analyses adjusting for receipt of additional nephrotoxins and age (selected as confounders a 
priori). Age was assessed as both a continuous variable and categorical variable (age greater 
than or less than 13 years). This cutoff was chosen as the constant values used to calculate 
creatinine clearance changes at age 13 years. Children with and without cystic fibrosis (CF) 
were compared because of anticipated differing dosing techniques, sites of infection and 
underlying medical conditions. The number of cases of colistin were regressed over time to 
determine if there was a significant change in prescription of colistin from 2005 to 2011. 
Data were analyzed using STATA 11 (STATA corp., College Station, TX) and a 2-sided P 
value <0.05 was considered statistically significant.
RESULTS
Of the 217 pediatric infectious diseases specialists completing the survey (84% response), 
22% had prescribed colistin to children. A total of 92 unique cases of colistin use between 
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2005 and 2011 from 25 institutions were submitted. Of the 92 cases reported, the majority 
(62%) were between 2010 and 2011 (Fig. 1).
Patient Characteristics
The median age of children receiving intravenous colistin was 16 years and ranged between 
2 months and 18 years. Children with CF receiving colistin tended to be older than children 
without CF (Table 1). The cases included in this study represent children from 
geographically diverse regions across the United States. Most (54%) patients resided in the 
Northeast region. Ten patients (11%) had a history of travel to or residence in another 
country within 30 days of admission. These countries included Greece, Haiti, Liberia, 
Mexico (3), Qatar, the United Arab Emirates (2) and Venezuela. CF was the most frequent 
underlying condition of children prescribed colistin (47%). Other common underlying 
medical conditions included tracheostomy dependency (14%), trauma (11%) and 
malignancy (10%) (Table 1). Eight (18%) children with CF and 46 (96%) children without 
CF were admitted to the intensive care unit during the time colistin was being administered.
Microbiology and Clinical Syndromes
The most common organism for which colistin was prescribed was P. aeruginosa. (Table 2) 
P. aeruginosa was isolated as a pathogen in 65 cases (71%) and in 62 of the cases was 
resistant to three or more classes of antibiotics. There were 11 cases of MDR A. baumanii 
(12%), 12 cases of carbapenemase-producing Entero-bacteriaceae (13%), and 5 cases of 
extended-spectrum β-lactamase producing Enterobacteriaceae (5%). Of note, 82% of 
children infected with MDR Acinetobacter were being managed in adult intensive care units 
for non-infectious issues and became infected with the organism after hospitalization.
Colistin was primarily used to treat ventilator-associated tracheitis and pneumonia (74%) 
followed by bacteremia (16%) and intra-abdominal abscesses (7%; Table 2). One patient 
received colistin both parenterally and intrathecally for an MDR P. meningitis. All children 
with CF included in the cohort were being treated for “CF exacerbations.” In the vast 
majority of children (91.3%), colistin was prescribed because the infectious pathogen was 
resistant to multiple antibiotic classes. In 8 (8.7%) cases, it was selected because of multiple 
patient allergies.
Administration of Colistin
Colistin was administered parenterally to all 92 patients. For children without CF, the initial 
colistin dose was most frequently 2.5 mg/kg every 12 hours, in accordance with the 
manufacturer’s insert;17 doses ranged from 1.25 to 5 mg/kg/dose in the absence of 
preexisting renal insufficiency (Table 1). For children with CF, 81% of patients began with 
an initial dose of 2.5 mg/kg every 8 hours. No providers administered an initial loading dose 
of colistin.
Concomitant antimicrobial therapy was administered in 77 (84%) patients, with the most 
common agents coadministered being aminoglycosides (26%), carbapenems (23%), 
fluoroquinolones (13%) and ceftazidime (12%); in 51 of these 77 cases (66%), the targeted 
organism was resistant to the second agent.
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Fifteen patients in the cohort (16%) died while receiving colistin therapy. Mortality was 
higher in the children without CF (25%). Although numbers were small, there was no 
difference in mortality between the children without CF receiving colistin monotherapy and 
combination therapy (P = 0.45). Within the CF and non-CF groups, mortality did not appear 
related to dose or interval of colistin prescribed (data not shown).
Forty-four children had subsequent cultures growing the same organism. Of these, resistance 
to colistin emerged in 9 (21%) children during the initial course of colistin therapy. None of 
the 9 children had CF, and they were all receiving combination therapy. Six of the children 
had catheter-related bacteremia without catheter removal. The remaining 3 children were 
being treated for ventilator-associated pneumonia. All 9 children continued to receive 
colistin therapy because of lack of alternative antibiotic agents and died during therapy.
Adverse Events
Overall, 27 patients (29%) experienced at least 1 adverse event attributed to colistin therapy. 
The most common adverse outcome reported was nephrotoxicity, which occurred in 21 
(22%) children. All cases of nephrotoxicity developed within 1 week of the first 
administered dose of colistin. One child required hemodialysis for acute renal failure 
attributed to colistin use. Renal function returned to baseline in all patients who survived 
after cessation of colistin, with creatinine normalizing a median of 5 days after its 
discontinuation. There was no association between dose or interval of colistin prescribed and 
the development of nephrotoxicity (P > 0.80). Age was associated with nephrotoxicity when 
modeled continuously (P = 0.04) and children aged ≥13 years had approximately 7 times the 
odds of developing nephrotoxicity than younger children, even after adjusting for the receipt 
of additional nephrotoxins (odds ratio 7.16; 95% confidence interval: 1.51–14.06; P = 0.01).
Four children (all with underlying CF) exhibited signs of neurotoxicity. Paresthesias were 
reported in 2 children which reversed in both cases within 2 days of discontinuation of the 
antibiotic. Two children developed persistent headaches after initiating colistin therapy 
which subsided after colistin was discontinued. All 4 children were exposed to colistin at a 
later time and had recurrence of these symptoms.
DISCUSSION
To increase understanding of the current use of colistin in children, we report findings from 
the largest case series of colistin therapy in children to date. Our results suggest that 
prescription of colistin may be increasing, likely mirroring the increase in MDR Gram-
negative organism infections in children, although clinical experience with this agent is still 
limited to a minority of pediatric infectious diseases practitioners. Although colistin appears 
to be prescribed more frequently, the use of colistin appears limited to the treatment of 
highly resistant organisms or when multiple allergies preclude the use of other classes of 
antibiotics. Our results indicate that in the United States, colistin is most commonly 
prescribed to children with CF with infections due to MDR P. aeruginosa.
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The optimal dose and interval of colistin administration for children remains uncertain. 
Recent studies suggest that the manufacturer’s recommended dose of colistin is suboptimal, 
leading to delays in achieving appropriate target drug concentrations.18–22 In our cohort, 
most children were prescribed colistin according to the manufacturer’s recommendation 
(2.5–5 mg/kg per day, divided into 2–4 equal doses, with interval adjustment recommended 
in renal impairment),17 and no difference in clinical response was observed regardless of the 
prescribed dose or interval within the CF group and non-CF groups. Because the children 
without CF were much more ill than children with CF, we did not compare clinical 
outcomes based on total daily dose or interval between these groups. Children with CF were 
generally administered higher total daily doses of colistin, typically 7.5 mg/kg/day divided 
in 8-hour intervals, presumably because of the higher volume of distribution in children with 
CF.23,24 This higher daily dose appears to be relatively well tolerated. In our cohort, no child 
received a loading dose of colistin. However, recent pharmacokinetic data suggest that 
plasma colistin concentrations may be insufficient before steady state, and patients may 
benefit from a colistin loading dose.22 It is noteworthy that according to recent clinical 
experience, higher daily doses of intravenous colistin, up to 720 mg per day, administered in 
large series of patients did not result in greater toxicity.25,26 More studies are needed to 
better elucidate the appropriate dose and interval of colistin administration and whether a 
loading dose may be necessary.
In our cohort, 84% of children received combination therapy, despite the majority of their 
pathogens exhibiting in vitro resistance to the additional agent. Although all children who 
developed resistance were receiving combination therapy, our study did not have adequate 
power to determine if combination therapy had an impact on preventing subsequent colistin 
resistance. Existing data do not demonstrate that combination therapy with colistin prevents 
the emergence of resistance.10 Because heteroresistance to colistin can occur relatively 
rapidly, the use of a second agent is sometimes advocated so at least 1 antimicrobial agent 
with some potential activity against the causative pathogen is being administered.18,27–30 In 
1 study, in vitro evidence of heteroresistance to colistin was reported to be as high as 93%,27 
though the clinical significance of heteroresistance identified in vitro remains unclear. 
Resistance to colistin emerged in 20.5% of children in our cohort, which is in accord with 
other studies reporting rates of resistance (range 3–27.9%).31–34 The mechanisms of colistin 
resistance are poorly defined and have been attributed to alterations in the bacterial outer 
membranes, electrolyte imbalances or production of efflux pumps.35,36 Existing data suggest 
that patients with colistin-resistant pathogens have increased mortality.37 All 9 patients who 
developed colistin resistance in our cohort died during therapy. These findings underscore 
the need for colistin to be prescribed judiciously taking into account that (1) prolonged use 
and suboptimal colistin levels may lead to the emergence of resistance and (2) treatment 
options for colistin-resistant organisms are often nonexistent.
Clinical studies concerning the synergistic activity of colistin with other antimicrobial agents 
in humans are limited. Similarly, data demonstrating improved clinical outcomes or the 
prevention of the emergence of resistance with combination regimens is lacking. Although 
our study did not demonstrate a survival benefit with colistin combination therapy, it did not 
have adequate power to evaluate this outcome. In vitro studies have demonstrated synergy 
when colistin is administered in combination with carbapenems and rifampin.38–42 
Tamma et al. Page 6













Colistin’s rapid destruction of outer membranes allows enhanced penetration of agents such 
as carbapenems and rifampin and is especially helpful when carbapenem resistance is a 
result of porin defects.38 Studies in adults have failed to show improved outcomes when 
combination therapy is used, but as these studies were observational, they may have been 
subject to confounding by indication.43–46 Although the role of combination therapy 
remains uncertain, combination therapy may nonetheless prove to be beneficial. As the 
distribution of colistin to the lung parenchyma, bones and cerebrospinal fluid is relatively 
poor, the addition of a second agent may ensure more acceptable antibiotic concentrations in 
these tissues.47,48
Nephrotoxicity was the most commonly observed adverse event in our cohort, which 
appeared to increase with age. Acute kidney injury generally became apparent within the 
first week of colistin initiation and in all cases reversed after discontinuation of colistin. In a 
retrospective study of 14 children who received colistin in the 1990s, Goverman et al 
reported a significant rise in creatinine in 2 children (14%).5 This is lower than colistin-
associated nephrotoxicity rates reported in the 1960s and 1970s, possibly due to 
improvements in supportive therapy and the decreased use of additional nephrotoxic agents 
in recent decades.16,49–51 A systematic review of case series and case reports on colistin use 
in children without CF by Falagas et al found the incidence of nephrotoxicity to be 2.8%.52 
Most children included in this review were hospitalized outside the United States, thus the 
generalizability to children in the United States should be interpreted with caution as a large 
portion of included children received doses of colistin lower than recommended by the US 
package insert.17,52 In recent adult literature, rates of nephrotoxicity range from 3.5 to 58% 
and appear to be dose dependent.9–16 Although it is unclear why adolescents and adults are 
predisposed to higher rates of nephrotoxicity than younger children, it may be related to 
baseline renal dysfunction and multiple minor injuries to the kidneys that have occurred over 
time. The definition of "nephrotoxicity" varies both within adult studies and between adult 
and pediatric studies.
Four patients in our cohort developed neurotoxicity, manifesting as paresthesias or severe 
headaches. These reversed in all patients but it is interesting to note that all patients who 
reported these symptoms on initial colistin use experienced them again when colistin was 
prescribed subsequently. Colistin-induced neurotoxicity appears to occur more frequently in 
children with CF (consistent with our data), although the cause is unclear. In 1 study of 31 
patients with CF receiving colistin, 68% experienced reversible paresthesias and/or ataxia.53
This study has several limitations to consider. First, this was a retrospective study where 
cases were ascertained by voluntary response to a survey of pediatric infectious diseases 
physicians. As a result, the representativeness of our findings is unknown; however, as there 
was an 84% response, we believe these findings are still largely generalizable. Second, the 
findings may be subject to recall bias. It is possible that physicians disproportionately 
submitted cases with more memorable outcomes. Similarly, they may have been more likely 
to recall recent cases. However, because colistin is infrequently administered to the pediatric 
population in the United States, we anticipate that physicians may remember most children 
to whom they prescribed colistin. Additionally, several of the authors reviewed their 
institution’s pharmacy databases and submitted all cases of colistin prescription in their 
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respective institutions in the past 7 years (n = 67) so these cases would not be subject to 
recall bias. Third, as not all patients had long-term follow-up, there may have been long-
term sequelae related to colistin use that was not captured by the study. Despite these 
limitations, these data provide important information to assist physicians with current 
practices regarding colistin use in children.
In conclusion, colistin use in children has been associated primarily with nephrotoxicity and, 
to a lesser extent, neurotoxicity, both of which were reversible in our cohort. The growing 
emergence of resistance is concerning. Pharmacokinetic studies to determine optimal dosing 
in children should be prioritized. Given the alarming emergence of MDR Gram-negative 
pathogens, prospective controlled studies assessing the efficacy and safety of colistin use in 
children are warranted.
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TABLE 1
Baseline Characteristics and Clinical Outcomes of 92 Children Receiving Intravenous Colistin Therapy
Overall
(n = 92; %)
Cystic Fibrosis
(n = 44; 48%)
No Cystic Fibrosis
(n = 48; 52%)
P*
Age (yr) 16 (11–17.5) 17 (15.5–18) 12.2 (3–17) <0.01
Dose in mg/kg (median, IQR) — 2.5 (2.2–2.5) 2.5 (1.625–2.5) 0.21
Interval (h; median, IQR) — 8 (8–8) 12 (8–12) <0.01
Travel to or from foreign country ≤30 d of current admission† 10 (10.9) 4 (9.1) 6 (12.5) 0.60
Intensive care unit admission 54 (58.7) 8 (18.2) 46 (95.8) <0.01
Underlying medical conditions
  Burns 3 (3.3) — 3 (6.8) 0.11
  Immunocompromised 17 (18.5) 6 (12.5) 11(25) 0.18
  Solid organ transplant‡ (lung, liver, kidney) 11 (12.0) 6 (12.5) 5 (11.4) 1.00
  Malignancy 9 (9.8) — 9 (20.5) <0.01
  Postoperative surgical site infection 4 (4.3) — 4 (9.1) 0.05
  Previously healthy child with recent trauma 10 (10.9) — 10 (22.7) <0.01
  Tracheostomy dependency 13 (14.1) — 13 (29.5) <0.01
Adverse drug events
  Clostridium difficile infection 1 (1.1) 0 1 (2.1) 1.00
  Gastrointestinal complains 2 (2.2) 1 (2.3) 1 (2.1) 1.00
  Nephrotoxicity 21 (22.3) 9 (20.5) 12 (48) 0.63
  Neurotoxicity 4 (4.3) 4 (9.1) — 0.05
  Rash 1 (1.1) 0 1 (2.1) 1.00
  Respiratory 2 (2.2) 1 (2.3) 1 (2.1) 1.00
Outcome
  Clinical cure§ — — 22 (45.9)
  Died while receiving intravenous colistin 15 (16.3) 3 (6.8) 12 (25) 0.02
*
Comparing children with and without cystic fibrosis.
†
Greece, Haiti, Liberia, Mexico (3), Qatar, the United Arab Emirates (2) and Venezuel.
‡
For the cystic fibrosis category, all transplants were lung transplants.
§
Because all 44 children with cystic fibrosis were being treated for a cystic fibrosis exacerbation with a resistant organism they were chronically 
colonized with, clinical cure was difficult to determine.
IQR indicates interquartile range.
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TABLE 2
Microbiological Data of Infections in 92 Children Receiving Intravenous Colistin Therapy
Overall
(n = 92; %)
Cystic Fibrosis
(n = 44; 48%)
No Cystic Fibrosis
(n = 48; 52%)
P*
Resistance profile of microorganisms identified*
  Extended-spectrum β-lactamase producer 5 (5.4) — 5 (10.4) 0.06
  Carbapenemase-producing Enterobacteriaceae 12 (13.0) 3 (6.8) 9 (18.8) 0.12
  MDR Achromobacter 2 (2.2) 2 (4.5) — 0.23
  MDR Acinetobacter 11 (12.0) 1 (2.3) 10 (22.7) <0.01
  MDR Pseudomonas 62 (67.4) 34 (77.3) 28 (58.3) 0.04
  MDR Stenotrophomonas 3 (3.3) 2 (4.5) 1 (2.1) 0.61
Site*
  Blood 15 (16.3) — 15 (31.3) <0.01
  Cerebrospinal fluid 1 (1.1) — 1 (2.1) 1
  Bone/wound 5 (5.4) — 5 (10.4) 0.36
  Intra-abdominal abscess 6 (6.5) — 6 (12.5) 0.03
  Respiratory tract 68 (74.1) 44 (100) 25 (52.1) <0.01
  Urine 3 (3.3) — 3 (6.3) 0.24
More than 1 response may apply to a patient.
*
Comparing children with and without cystic fibrosis.
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